Confo - Superior Platform for Structure-Based Drug Design
From Technology
With its unique antibody-based technology, Confo Therapeutics aims to overcome the current limitations of GPCR drug discovery in order to fully realize the potential of GPCRs as drug targets.
-
Most popular related searches
Details
ConfoBodies®
Our drug discovery engine uses advanced antibody technology, ConfoBodies,
to enable superior and more efficient drug discovery for dynamic membrane proteins in their natural environment.
A ConfoBody is a single-domain antibody (VHH), generated using our proprietary processes, that binds to and stabilizes the protein in its therapeutically relevant conformation, for example in the agonist-bound active state. Our team has over 10 years of experience in ConfoBody discovery, employing a suite of VHH discovery techniques.
We have developed highly sensitive and selective screening assays which enable us to focus our screening efforts on the therapeutically relevant confirmation with ConfoBodies. We use ConfoBodies and MegaBodies® to stabilize the protein target in its disease-relevant state for structure-based drug design.
Customer reviews
No reviews were found for Confo - Superior Platform for Structure-Based Drug Design. Be the first to review!